GSK announced a major breakthrough concerning cancer therapy. A drug called Jemperli (dostarlimab) showed impressive results in a phase 2 trial at the Memorial Sloan Kettering Cancer Center (MSK).

In what can be termed a never-seen-before medical miracle, a small group of people with colorectal cancer achieved 100% ...

The drugmaker remains convinced of the potential of the drug, however, and has just reported results of a trial comparing Jemperli (dostarlimab ... non-small cell lung cancer (NSCLC) that has ...

The approval is based on the RUBY trial, which showed that Jemperli (dostarlimab ... is a key approval for the drug as it fends off a challenge in endometrial cancer from MSD's rival PD-1 ...

This trial is looking at dostarlimab by itself and with other immunotherapies ... GSK6097608 is another monoclonal antibody that blocks a protein called CD96 on the cancer cells. Research shows that a ...

Detailed price information for Lixte Biotech Hlds (LIXT-Q) from The Globe and Mail including charting and trades.